Sexually Transmitted Diseases

Both organizations will invest $100 million to develop and advance candidate gene-based cures for HIV and sickle cell disease to clinical trials within 10 years.

Universal screening identifies cases in those who do not consider themselves at risk and helps re-link previously known patients who have fallen out of treatment back to care.

Gregory Felzien, MD, discusses the surprising benefits HIV clinics encounter when they enhance community engagement.

A medication that secretes growth hormone is shown to reduce liver fat in an HIV-positive population, and investigators would like to see it used more widely.

Max Brito, MD, MPH, discusses his presentation from IDWeek 2019 which compared HIV treatment in a community-based model versus a hospital-based model in Chicago.

Gregory Felzien, MD, AAHIVS, discusses prevention beyond PrEP and creating a safe environment for patients with HIV.

Given a general rise in STD cases, clinicians treating ESRD may have to pay special attention to possible coinfections.

Pooled analysis linked baseline demographics, including lower CD4 count, higher HIV-1 RNA, no history of injection drug use, female sex, and black race, to weight gain following ART initiation.

The ECDC 2019 plan to address multi- and extensively-drug resistant gonorrhea has been released.

The latest report from the CDC shows that preventable infections are on the rise nationally. Particularly hard hit are women, young people, minority groups, and infants exposed to syphilis.

Gregory Felzien, MD, AAHIVS, discusses barriers to HIV care, particularly in neglected rural areas.

When the CD4 count seems too good to be true.

A study suggests young black MSM can experience delays in PrEP initiation if they do not have health insurance, even if expanded access through manufacturer assistance programs is offered.

The study focused on women living with HIV in areas where TB is highly prevalent.

Investigators with The University of Texas Health Science Center embarked on a study to determine whether HIV disclosure at the emergency department should be based on preliminary results.

Patients with a new diagnosis of HIV may benefit from rapid start of ART.

Anandi Sheth, MD, MSc, summarizes her presentation on HIV prevention in women and discusses the need for more women in pre-exposure prophylaxis research.

Jason Schafer, PharmD, MPH, BCPS AQ-ID, previews the October issue featuring an article on rapid initiation of antiretroviral therapy.

HIV testing rates have improved among men who have sex with men in Africa, but new research indicates the developments are not enough to meet the UNAID’s 90-90-90 targets.

University of Illinois at Chicago investigators compared virologic failure among MSM and transgender women receiving HIV care at a community-based model with those receiving care at a hospital-based model.

For individuals living with HIV, switching suppressive HIV regimens may be considered for a variety of reasons including treatment simplification, improved safety and tolerability, drug-drug interactions, or cost.

ART-related medication errors can occur and lead to suboptimal therapy and in some cases treatment resistance.

Approximately ≥60% of men who have sex with men (MSM) find sexual partners via the internet, primarily through Grindr, which is the most popular dating app among MSM.

In general, women shared many of the same positive perceptions of long-acting ART that men did but offered unique insight.

The study investigators conclude that U=U awareness seems to be improving among GBMSM, with HIV-negative individuals making the most progress.

The mobile unit provided services to 229 clients from October 2018 to April 2019, 168 (73.7%) of whom sought PrEP.

A 7-year study highlights the ability of an ultra-long-acting injectable implant to elute HIV drug combinations for months at a time.

In order to overcome the barriers to HIV care, it is important for both patients and health care professionals to mutually agree that a particular strategy is useful.

The FDA has approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF).

Awareness for HIV PrEP was high for all racial and ethnic groups, but black and Hispanic MSM discussed its use with physicians less often than white counterparts.